Miridesap (GSK2315698) is a divalent cross-linking agent that rapidly depletes serum amyloid P component (SAP) from circulation through hepatic clearance, while also reducing SAP levels in cerebrospinal fluid and visceral amyloid deposits. It is utilized in in vivo research models of systemic amyloidosis to study amyloid dissolution and clearance mechanisms.
